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Abstract
Background/Aims. Our policy for the surgical treatment of hepatocellular carcinoma (HCC) has been to minimize the extent
of liver resection using a microwave tissue coagulator (MTC) and to not perform Pringle’s maneuver for the prevention of
ischemic injury to the liver routinely. We verify the safety of liver resection using MTC in HCC patients with poor liver
functional reserve, and clarify the long-term outcome of HCC patients who underwent curative resection using MTC.
Methodology. One hundred sixty-eight patients who underwent curative resection using MTC between 1992 and 2001 were
divided into two groups according each patient’s score in the Indocyanin Green Retension 15 Test (ICG-R15 test). The
high (ICG-R15 values20) and low ICG-R15 groups (ICG-R15 valuesB20) included 100 and 68 HCC patients,
respectively. Clinical characteristics of each group were evaluated, and operative mortality and morbidity, as well as overall
and disease-free survival rates, were compared between the two groups to determine risk factors for overall and disease-free
survival. Results. Although there were significant differences in liver function-related parameters between the low and high
ICG-R15 groups, no differences in surgical or tumor factors were found. No patients in this study developed post-operative
liver failure, and there was no significant difference in morbidity between the low and high ICG-R15 groups. The overall
survival rate of the low ICG-R15 group was significantly longer than the high ICG-R15 group (p0.0003). Cox’s
multivariate analysis showed that an ICG-R15 value less than 20 was the only significant independent factor for overall
survival. Disease-free survival rates in the low ICG-R15 group were significantly longer than in the high ICG-R15 group
(p0.0007). Multivariate analysis showed that serum albumin level and number of tumors were significant independent
factors for disease-free survival. Conclusion. The long-term outcome of HCC patients with low ICG-R15 following curative
resection using MTC was acceptable. This procedure was safe even for patients with high ICG-R15.
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Introduction
Hepatocellular carcinoma (HCC) is the fifth most
common cancer in the world [1]. With the exception
of liver transplantation for limited cases [2] and
percutaneous local ablative therapy for patients with
a solitary and small HCC [3], liver resection remains
the most effective radical approach for HCC treat-
ment. As post-operative mortality and morbidity rates
have decreased and long-term outcome has improved,
the number of liver resections performed to treat
HCC has increased. New techniques have been
introduced for safe and effective liver resection. To
reduce intra-operative blood loss that correlates with a
higher rate of post-operative complication and a
shorter survival time, hypotensive anesthetics, Prin-
gle’s maneuver [4], and new devices to transect liver
parenchyma [514] have been introduced.
The microwave tissue coagulator (MTC), devel-
oped in 1979 by Tabuse [15], has been applied
clinically to the transection of hepatic parenchyma
with or without liver cirrhosis. Use of the MTC has
been reported to reduce blood loss and to enable non-
anatomical liver resections, even in patients with poor
liver functional reserve [1518]. Our policy for the
surgical treatment of HCC has been to minimize the
extent of liver resection and to not perform Pringle’s
maneuver [4] for the prevention of ischemic injury to
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the liver routinely. We reported previously that 214
consecutive patients with HCC underwent non-ana-
tomical liver resections using MTC safely with
acceptable short-term results and no need for other
special techniques [19]. Here we verify the safety of
liver resection using MTC in HCC patients with poor
liver functional reserve, and clarify the long-term
outcome of HCC patients who underwent curative
resection using MTC.
Patients and methods
Between April of 1992 and December of 2001, 270
consecutive patients with HCC underwent liver re-
section in our hepato-pancreatobiliary unit. Of these
patients, 214 cases underwent liver resection using a
MTC. The remaining 56 cases were excluded from
the present analysis for having undergone right/left
lobectomy or lateral segmentectomy without using the
MTC. Of the 214 patient treated with the MTC, 168
patients who underwent curative resection were di-
vided into two groups according to test values for
retension of Indocyanin Green Retension 15 Test
(ICG-R15 test). High (ICG-R15 values20) and low
(ICG-R15 values520) scoring ICG-R15 groups con-
sisted of 100 and 68 HCC patients, respectively.
‘‘Non-curative resection’’ implies that cancer cells or
tissues were not removed pathologically by the surgi-
cal procedure, or that both liver resection and local
ablation therapy were performed simultaneously on
multiple tumors in bilateral lobes of the liver. The
presence of a tumor thrombus at the IVC, hepatic
vein or portal vein also resulted in classification into
the ‘‘non-curative resection’’ category. Data were
collected from the prospective HCC database at
Kansai Medical University Hospital. This study was
done in accordance with the Helsinki Declaration of
1975.
Perioperative clinical parameters including patient
characteristics, preoperative liver function data, op-
erative factors and tumor characteristics were col-
lected (Table 1). We used the General Rules for the
Clinical and Pathological Study of Primary Liver
Cancer by the Liver Cancer Study Group of Japan
as guidelines for staging [20]. Overall survival rate was
calculated and defined as the interval between the
date of surgery and the date of death (or the date of
last follow-up for living patients). Causes of death
included cancer, as well as others such as cerebral
bleeding, post-operative bleeding, sepsis, etc. Dis-
ease-free survival, defined as the interval between the
date of surgery and the date that a diagnosis of
recurrence was confirmed by a positive sonogram,
computed tomograph, magnetic resonance image or
hepatic angiograph, was also evaluated.
All patients were followed monthly, and routine
liver biochemical tests were conducted every three
months at the central hospital laboratory. Liver
Table 1. Patient characteristics.
Parameters ICG-R15B20 n100 ICG-R1520 n68 p-value
Patient factor
Age (y.o.) 65(3780) 64(3678) n.s.
Male:female 83(83):17(17) 48(71):20(29) n.s.
Liver cirrhosis: no cirrhosis 29(29):71(71) 46(68):22(32) B0.0001
Viral status (type C:type B:none) 64(64):22(22):14(14) 58(86):5(7):5(7) 0.0062
Prothrombin time (%) 91(45117) 82(62116) B0.0001
Total Bil (mg/dl) 0.7(0.31.7) 1.0(0.51.9) B0.0001
Albumin (g/dl) 4.0(3.14.9) 3.6(2.74.6) B0.0001
AST (U/l) 40(12198) 55(19154) B0.0001
ALT (U/l) 46(10195) 48(10213) n.s.
Platelet count (109) 13.4(3.843.4) 10.0(4.124.1) B0.0001
Alpha-feto protein 17(516223) 33(54473) 0.0183
DM (:) 58(58):42(42) 39(58):27(42) n.s.
Surgical factor
Op time (min) 253(110650) 248(85515) n.s.
Blood loss (ml) 848(2015140) 983(508475) n.s.
Blood transfusion (:) 42(42):58(58) 32(47):36(53) n.s.
Blood transfusion (pack) 0(041) 0(034) n.s.
Tumor factor
Tumor in diameter (cm) 3.0(0.425) 2.8(0.78) n.s.
Number of nodules 1(15) 1(13) n.s.
Solitary vs Multiple 94(94):6(6) 60(88):8(12) n.s.
Tumor differentiation (well:mod:por) 23(23):71(71):6(6) 13(19):51(75):4(6) n.s.
Vascular invasion (:) 44(44):56(56) 21(33):47(69) n.s.
T category (I/II:III/IV) 63(63):37(37) 50(74):18(26) n.s.
Staging (I:II:III:IV) 59(59):41(41) 45(66):23(34) n.s.
Note: Table shows median value (range) or number of patients (%).
Bil: Bilirubin; AST: Aspartate transaminase; ALT: Alanine transaminase; DM: diabetes mellitus.
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ultrasound was performed every three months, and
computed tomography and/or magnetic resonance
imaging were performed at least every six months.
Finally, admitted patients underwent angiographic
studies when a recurrence was suspected. Upon
confirmation of an intra-hepatic recurrence, patients
generally received transarterial chemoembolization
(TACE), local ablation therapy, and/or re-resection
depending on liver function and on the patient’s
desire.
Microwave tissue coagulator (MTC)
Basic information and clinical applications of the MTC
have been reported in detail by K. Tabuse (a pioneer in
the surgical applications of microwave radiation) [21].
This microwave system burns tissue and destroys all
tissue structures, including the major blood vessels,
within microwave range. The MTC consists of a basic
needle applicator and a 2.45 GHz (150W) generator
(trade name of Microtaze, Figure 1A) produced by
Alfresa co. Osaka, Japan. The MTC heats liver
parenchyma to affect coagulation by internal radiation
via a coaxial needle antenna. As shown in Figure 1A,
the needle applicator consists of a 10 mm, 15 mm, or
20 mm length electrode and its base. The level of power
employed varied from 60 to 80 W, and coagulation and
dissociation times were 45 and 15 sec, respectively. To
withdraw the needle radiators easily from the coagu-
lated tissue, the Microtaze generator has a dissociation
function.
Operative procedure
After laparotomy, tumor location and its relationship
to Glisson’s sheath and hepatic veins were determined
following liver exposition using intraoperative ultra-
sonography. As shown in Figure 1B-i, and previously
in Tabuse et al. [15] and Ryu et al. [16], liver tissue
coagulates during repeated insertion of a monopolar
MTC needle electrode along the intended resection
line, 23 cm away from the tumor. Coagulated liver
tissue was dissected and routinely crushed with
forceps without Pringle’s procedure (Figure 1B-ii,
iii). Any exposed blood vessels were ligated with
sutures.
Statistics
Data were organized using MicrosoftTM Excel and are
expressed as median (range). Statistical analyzes,
including Mann-Whitney U test and Fisher’s exact
Figure 1. Microwave tissue coagulator electrode and operative procedure. The microwave tissue coagulator heats liver parenchyma by
internal radiation via a coaxial needle antenna to effect coagulation. (A) The needle applicator consists of a 10-, 15-, or 20-mm length
electrode and its base. (B, i) The liver parenchyma coagulated by repeated insertion of a monopolar MTC needle electrode along the
intended resection line, 23 cm away from the tumor. (B, ii and iii) dissection of the coagulated liver tissue with forceps, routinely without
Pringle’s procedure.
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test, were performed using Statview Version 5.0 for
Windows (Abacus Concepts, Inc. USA). Kaplan-
Meier survival curves were plotted, and log rank tests
were performed. For analysis of overall survival and
disease-free survival risk factors, univariate or multi-
variate analysis were performed using Cox’s analysis.
P values less than 0.05 were considered significant.
Results
Patient backgrounds
Patient, surgical, and tumor characteristics are shown
in Table 1. Among 168 patients, 45% were diagnosed
histologically as liver cirrhosis. Hepatitic viruses B and
C were found in 73 and 16% of patients, respectively.
The median tumor diameter was 3.0 cm, and 78% of
patients had only one HCC at surgical resection.
Median operative duration and blood loss was
250 min and 902 ml, respectively. Forty-four percent
of patients received a blood transfusion. Although
there were significant differences in liver function-
related parameters between low and high ICG-R15
groups, no differences in surgical and tumor factors
were found.
Post-operative complications
Post-operative mortality and morbidity rates were 1.8
and 34%, respectively. Three in-hospital deaths oc-
curred in the high ICG-R15 group (two from multiple
organ failure due to intra-abdominal bleeding and one
from sepsis). No cases of post-operative liver failure
developed in this study. Although there was no
significant difference in morbidity between the low
and high ICG-R15 groups was found, there was a
trend toward higher morbidity in the high ICG-R15
group (41% vs. 29%). There were no differences in
the frequencies of uncontrollable pleural effusion and
ascites, bile leakage, abscess formation, ileus, wound
infection or prolonged liver dysfunction between
groups.
Overall survival
The overall survival rates for all patients at one, three
and five years were 98, 83 and 67%, respectively.
There were significant differences in overall survival
rates between groups (p0.0003, Figure 2): In the
low ICG-R15 group, survival rates at one, three, and
five years were 98, 88, and 75%, respectively, sig-
nificantly longer than 97, 76 and 53%, in the high
ICG-R15 group. ICG-R15 and serum albumin levels
abstracted from the results using Cox’s univariate
analysis were included in a multivariate analysis
identifying ICG-R15B20% as the only significant
independent factor for overall survival (Table 2).
Disease-free survival
Disease-free survival rates at one, three and five years
for all patients were 83, 47 and 29%, respectively.
Disease-free survival rates in the low ICG-R15 group
were 84, 58, and 37%, at one, three, and five years,
respectively. These values were significantly longer
than 81, 31 and 16% at one, three, and five years in
the high ICG-R15 group (p0.0007, Figure 2). Cox’s
univariate analysis showed that the five variables shown
in Table II were all independent factors that associated
significantly with disease-free survival. Multivariate
analysis showed that serum albumin level and number
of tumors were independent factors that associated
significantly with disease-free survival (Table 2).
Sites of recurrence
By the end of the observation period, 121 patients had
tumors reoccur initially in the liver (n111, 66%) or
extrahepatic sites (n10, 6%). Tumor recurrence in
the liver was solitary in 44 patients (40%) and
multiple in 67 patients (60%). Only four patients
(2%) showed a recurrent tumor near the cut surface
of the liver as well as multiple recurrences by
radiological examination. There was no difference in
sites of initial recurrence between the low and high
Figure 2. Overall and disease-free survival curves in low- versus high-ICG-R15 group patients Solid and broken lines indicate survival
curves in the low and high ICG-R15 groups, respectively. Overall survival rates in the low ICG-R15 group (98, 88 and 75% at one, three
and five years, respectively) were significantly longer (p0.0003) than in the high ICG-R15 group (97, 76 and 53% at one, three, and five
years, respectively). Disease-free survival rates in the low ICG-R15 group (84, 58 and 37% at one, three, and five years, respectively) were
significantly longer (p0.0007) than in the high ICG-R15 group (81, 31 and 16%, at one, three, and five years, respectively).
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ICG-R15 groups. One hundred and thirteen patients
(93%) underwent post-recurrence treatment, whereas
eight patients (7%) received no treatment due to poor
liver function or patient’s wish. Treatments for
recurrence among the 113 patients included TACE
for 87 (77%), local ablation therapy for 11 (10%), re-
resection for 12 (11%), and systemic chemotherapy
for three (2%). There was no significant difference in
treatments for recurrence between the low and high
ICG-R15 groups.
Discussion
Although surgical resection represents the best hope
for long-term survival in patients with HCC, large
amounts of sacrificed non-tumorous liver could re-
strict surgical indications to avoid post-operative liver
failure. Our policy for the surgical treatment of HCC
has been to minimize the extent of liver resection and
to not perform Pringle’s maneuver for the prevention
of ischemic injury to the liver routinely. We performed
non-anatomical liver resections using MTC in accor-
dance with tumor size. In some cases, liver resections
with exposure of the tumor surface at the cut surface
of the remnant liver were performed with no surgical
margins due to tumor adherence to major hepatic
vascular structures or localization to the liver center.
We have reported that no significant differences in
overall and disease-free survival rates were found
between patients who underwent liver resection with
or without surgical margins [22]. Poon et al. [23]
suggest that aggressive treatments with multi-modal
strategies in HCC patients with intra-hepatic recur-
rence after curative resection could prolong survival.
In our facility, successful results have been achieved
using active hexose-correlated compound (AHCC), a
functional food developed by the Amino Up Chemical
Co. Ltd (Sapporo, Japan) [24]. Intake of AHCC
improved liver function, prevented recurrence of
HCC after resection, and prolonged survival of post-
operative HCC patients without any adverse effects.
Our previous report demonstrated that liver resec-
tion using MTC can be safe and effective [19].
Moreover, common independent prognostic factors
for survival and disease-free survival in multivariate
analyzes included ICG-R15 score and type of curative
resection. In this report, we verify that in HCC
patients, the safety and long-term outcome of curative
resection using MTC. This study demonstrated that
overall and disease-free survival rates in patients with
low ICGR15 were significantly better than that in
patients with high ICG-R15. There were no signifi-
cant differences between the two groups in operative
time, extent of blood loss or post-operative complica-
tions in liver resection using MTC. There were no
deaths following post-operative liver failure. Thus, the
long-term outcome following curative resection using
MTC was acceptable for HCC patients in the low
ICG-R15 group, and this type of operation proved
safe even for patients in the high ICG-R15 group.
Both surgical curability and post-operative liver
functional reserve are generally considered crucial
for the successful treatment of patients with HCCs
[2528]. According to a nationwide survey in Japan in
2003 [29], 44% of HCC patients treated with surgery
had pathologically proven liver cirrhosis and 47% had
chronic hepatitis which can result in poor liver
reserves. Among the patients in this study, half had
Table II. Multivariate analysis for overall and disease-free survival.
Significant variables b SE HR (95%CI) p
Overall survival
ICG-R15 (%)
(]20 vs. 1020) 0.545 0.240 0.580 (0.3620.929) 0.0234
(]20 vs. B10) 0.872 0.373 0.418 (0.2010.869) 0.0194
Basal albumin (g/dl)
(]3.7 vs. B3.7) 0.388 0.227 0.678 (0.4341.059) 0.0878
Disease-free survival
Basal albumin (g/dl)
(]3.7 vs. B3.7) 0.462 0.209 0.630 (0.4180.950) 0.0273
ICG-R15 (%)
(]20 vs. B20) 0.364 0.214 0.695 (0.4571.057) 0.0891
Number of tumor
(1 vs. 1) 0.726 0.294 2.067 (1.1623.667) 0.0135
Total Bilirubin
(]1.1 vs. B1.1) 0.356 0.206 1.428 (0.9542.137) 0.0835
Staging
(IV vs. I) 0.866 0.534 0.412 (0.1451.174) 0.0971
(IV vs. II) 0.706 0.508 0.494 (0.1821.336) 0.1645
(IV vs. III) 0.543 0.506 0.581 (0.2151.566) 0.2830
Note: b: regression coefficients; SE: standard error; HR: hazard ratio; CI: confidence interval; ICG-R15: indocyanine green retention test.
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pathologically proven liver cirrhosis and 89% were
positive for hepatitis virus (17% with type B and 72%
with type C hepatitis). Moreover, 40% of the patients
in this study with ICGR15 levels greater than 20%
were not considered good candidates for hemi-hepa-
tectomy. Overall patient survival rates in this study
were 98, 83 and 67% at one, three, and five years,
respectively, which were similar to nation-wide survey
results in Japan (92, 74 and 58% at one, three, and
five years, respectively) [29].
Progression of liver disease following liver resection
can be due not only to tumor recurrence but also to
liver decompensation. Because these events represent
the main causes of death, the balance between
surgical curability and preservation of remnant liver
function is of great importance. Although there is a
concern of recurrence in the remnant liver, smaller
surgical margins could better prevent post-operative
complications (including liver failure), particularly in
patients with cirrhosis. In the high ICG-R15 group in
this study, non-anatomical liver resection using MTC
was a safe procedure; however, overall and disease-
free survival were still significantly lower in the high
ICG-R15 group than in the low ICG-R15 group.
Ercolani et al. have reported that well-compensated
cirrhotic patients with a single HCC are good
candidates for liver resection, but that they carry a
high risk of de novo tumors due to the multifocal
carcinogenic potential of cirrhosis [30]. In regard to
liver function and surgical curability, liver transplan-
tation is considered the ideal treatment for HCC in
cirrhotic patients. However, due to the limited avail-
ability of donor organs and consequent delays in
transplantation [31], non-anatomical liver resection
using MTC remains a valid surgical option for
cirrhotic patients with HCC.
Historically, liver surgeons devised several techni-
ques for safe and effective liver resection: Inflow
occlusion of the Pringle maneuver has been used
since the early 20th century [4] to prevent intra-
operative bleeding during parenchymal transection,
which is associated with a higher rate of post-operative
complication and a shorter survival time. To control
bleeding from the hepatic veins, concomitant use of
low central venous pressure (CVP) was then applied
[32,33]. However, because both the Pringle maneuver
and low CVP can result in liver damage due to
ischemia and reperfusion injury, new devices to
transect liver parenchyma, including the suction knife,
ultrasonic dissector, YAG laser, water jet, dissecting
sealer and MTC, have been introduced [514].
Two randomized controlled trials (RCTs) compar-
ing the traditional clump crushing technique to some
of these new devices have been reported. For transec-
tion of the liver using the Pringle maneuver, Ta-
kayama et al. [5] concluded that ultrasonic dissection
offered no reduction in blood loss relative to clamp
crushing, and they recommended clamp crushing for
liver resection. Recently, Lesurtel et al. [34] reported
that relative to Cavitron Ultrasonic Surgical Aspirator
(CUSA), hydrojet or dissecting sealers, clamp crush-
ing was the most efficient device in terms of resection
time, blood loss and blood transfusion frequency, and
also the most cost-efficient device in non-cirrhotic and
non-cholestatic patients. Ironically, these RCTs re-
vealed that the efficacy of these expensive devices to
transect liver parenchyma was less than or equal to the
simple method of clamp crushing. RCT studies
comparing microwave surgery to clamp crushing are
still needed.
In conclusion, using MTC during curative liver
resection in HCC patients with low ICG-R15 values
resulted in acceptable long-term outcomes. This type
of operation was also safe procedure for patients with
high ICG-R15. Although liver transplantation re-
mains the ideal treatment for HCC in cirrhotic
patients with regard to liver function and surgical
curability, the present situation of limited donor organ
availability and transplantation delay promotes non-
anatomical liver resection using MTC as an immedi-
ate and viable surgical option for cirrhotic patients
with HCC.
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